JP2011526622A - クエチアピンを含む徐放性医薬組成物 - Google Patents

クエチアピンを含む徐放性医薬組成物 Download PDF

Info

Publication number
JP2011526622A
JP2011526622A JP2011515737A JP2011515737A JP2011526622A JP 2011526622 A JP2011526622 A JP 2011526622A JP 2011515737 A JP2011515737 A JP 2011515737A JP 2011515737 A JP2011515737 A JP 2011515737A JP 2011526622 A JP2011526622 A JP 2011526622A
Authority
JP
Japan
Prior art keywords
dosage form
sustained release
release dosage
quetiapine
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011515737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526622A5 (enExample
Inventor
アビナシュ クリシュナジ ベルハル
スニル アナントラオ ミラジカル
ビレンドラ ランクルパル クリル
ヴィニート ラグハバン
ニナド デシュパンデイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of JP2011526622A publication Critical patent/JP2011526622A/ja
Publication of JP2011526622A5 publication Critical patent/JP2011526622A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011515737A 2008-07-01 2009-06-29 クエチアピンを含む徐放性医薬組成物 Pending JP2011526622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1143KO2008 2008-07-01
IN1143/KOL/2008 2008-07-01
PCT/IN2009/000369 WO2010001413A2 (en) 2008-07-01 2009-06-29 Sustained release pharmaceutical compositions comprising quetiapine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014125631A Division JP2014196334A (ja) 2008-07-01 2014-06-18 クエチアピンを含む徐放性医薬組成物

Publications (2)

Publication Number Publication Date
JP2011526622A true JP2011526622A (ja) 2011-10-13
JP2011526622A5 JP2011526622A5 (enExample) 2012-08-16

Family

ID=40957738

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011515737A Pending JP2011526622A (ja) 2008-07-01 2009-06-29 クエチアピンを含む徐放性医薬組成物
JP2014125631A Pending JP2014196334A (ja) 2008-07-01 2014-06-18 クエチアピンを含む徐放性医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014125631A Pending JP2014196334A (ja) 2008-07-01 2014-06-18 クエチアピンを含む徐放性医薬組成物

Country Status (6)

Country Link
US (1) US8440223B2 (enExample)
EP (1) EP2309994A2 (enExample)
JP (2) JP2011526622A (enExample)
AU (1) AU2009265099A1 (enExample)
WO (1) WO2010001413A2 (enExample)
ZA (1) ZA201100635B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
WO2013095312A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprising quetiapine fumarate
US20150231080A1 (en) * 2012-09-10 2015-08-20 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2014155387A1 (en) * 2013-03-24 2014-10-02 Tushar Patel Extended release dosage forms of quetiapine salts
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
CN104523600A (zh) * 2014-11-21 2015-04-22 哈尔滨圣吉药业股份有限公司 一种富马酸喹硫平缓释微丸及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0658877A (ja) * 1992-08-11 1994-03-04 Daicel Chem Ind Ltd 酢酸セルロース中のゲル量の評価方法
JP2002535353A (ja) * 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
JP2006219502A (ja) * 1994-04-22 2006-08-24 Astellas Pharma Inc 結腸特異的薬物放出システム
WO2007000778A2 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
JP2007509155A (ja) * 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
JP2010532746A (ja) * 2007-01-25 2010-10-14 パナセア バイオテック リミテッド 放出調節医薬組成物およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
EP2457563B1 (en) 2006-05-09 2017-03-22 Mallinckrodt LLC Zero-order modified release solid dosage forms
US20110052648A1 (en) * 2008-03-12 2011-03-03 Avi Avramoff Oral modified-release formulations containing thiazepines
US7794750B2 (en) 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
SI2262486T1 (sl) * 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Sestavek kvetiapina

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0658877A (ja) * 1992-08-11 1994-03-04 Daicel Chem Ind Ltd 酢酸セルロース中のゲル量の評価方法
JP2006219502A (ja) * 1994-04-22 2006-08-24 Astellas Pharma Inc 結腸特異的薬物放出システム
JP2002535353A (ja) * 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
JP2007509155A (ja) * 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
WO2007000778A2 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
JP2010532746A (ja) * 2007-01-25 2010-10-14 パナセア バイオテック リミテッド 放出調節医薬組成物およびその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNYA FUJIMORI, ET. AL.: ""Application of Eudragit RS to Thermo-Sensitive Drug Delivery Systems. I. Thermo-Sensitive Drug Rele", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 50, no. 3, JPN6014006189, 2002, pages 408 - 412, ISSN: 0002746614 *

Also Published As

Publication number Publication date
US20110151002A1 (en) 2011-06-23
ZA201100635B (en) 2011-10-26
US8440223B2 (en) 2013-05-14
JP2014196334A (ja) 2014-10-16
WO2010001413A2 (en) 2010-01-07
AU2009265099A1 (en) 2010-01-07
EP2309994A2 (en) 2011-04-20
WO2010001413A3 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
JP2014196334A (ja) クエチアピンを含む徐放性医薬組成物
EP2854759B1 (en) Dosage forms comprising apixaban and matrix former
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
EP2200591A2 (en) Controlled release pharmaceutical dosage forms of trimetazidine
NO330260B1 (no) Oral, fast sammensetning omfattende levodopa/carbidopa/entacapon, fremgangsmate for fremstilling derav, samt anvendelse av en sammensetning omfattende levodopa/carbidopa/entacapon for fremstilling av et medikament til behandling av Parkinsons sykdom.
CN104922683A (zh) 含有蜡的缓释制剂
HUP0401978A2 (hu) Tamszulozintabletták
DK178741B1 (da) Oral farmaceutisk sammensætning med langvarig frigivelse omfattende hydromorphon og naloxon til anvendelse ved behandling af moderate til svære smerter.
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
AU2013302359A1 (en) Pharmaceutical compositions of Memantine
CZ2004931A3 (cs) Pevná formulace s kontrolovaným uvolňováním léčiva jako dávkovací systém se sníženým rizikem
US20090088424A1 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
US10709699B2 (en) Pyridone derivative pharmaceutical composition and preparation method thereof
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
CA2918707A1 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
JP2023052494A (ja) 抗凝固薬の即時放出医薬製剤及びその調製方法
WO2017029225A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
US20130209553A1 (en) Extended release pharmaceutical compositions of pramipexole
WO2018102526A1 (en) Pharmaceutical dosage form
WO2018130943A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
CN105492013B (zh) 用于管理恶心和呕吐的组合物
AU2022342749A1 (en) Pharmaceutical composition of bempedoic acid
CN104997749A (zh) 控制释放制剂及其制备方法与用途
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140618